Metropolitan Life Insurance Company (MetLife)’s Aegerion Pharmaceuticals AEGR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-21,705	Closed	-$219K	–	2561
2015 Q4	$219K	Hold	21,705	–	–	﹤0.01%	2203
2015 Q3	$295K	Hold	21,705	–	–	﹤0.01%	1995
2015 Q2	$412K	Sell	21,705 -1,528	-7%	-$33.1K	﹤0.01%	1879
2015 Q1	$608K	Hold	23,233	–	–	﹤0.01%	1455
2014 Q4	$486K	Hold	23,233	–	–	﹤0.01%	1784
2014 Q3	$776K	Hold	23,233	–	–	0.01%	1440
2014 Q2	$746K	Hold	23,233	–	–	0.01%	1547
2014 Q1	$1.07M	Hold	23,233	–	–	0.01%	1297
2013 Q4	$1.65M	Buy	23,233 +666	+3%	+$50.9K	0.01%	1066
2013 Q3	$1.93M	Sell	22,567 -1,004	-4%	-$85.1K	0.01%	952
2013 Q2	$1.49M	Buy	+23,571	New	+$1.25M	0.01%	1031

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s AEGR Position: Q1 2016 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 21,705 shares — an estimated $219K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AEGR in Q2 2013 and held it in 11 quarters. The position peaked at $1.93M in Q3 2013. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

Metropolitan Life Insurance Company (MetLife) reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 21,705 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $219K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s Aegerion Pharmaceuticals position peaked at $1.93M in Q3 2013.
101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2016, filed 16 May 2016.